Document is current
Any future updates will be listed below
-
Authors
Maso, Lorenzo
Mosure, Sarah A.
Rodriguez-Aponte, Sergio A.
Pizzo, Angelina
Mensah, Diamond N.
Southard, Matthew
Sze, Samantha
Ahmed, Tanvir
Vash, Brian
Hattori, Takamitsu https://orcid.org/0000-0002-5502-2595
Rajak, Epsa https://orcid.org/0009-0006-6944-2618
Koide, Akiko https://orcid.org/0000-0003-1796-7077
Neel, Benjamin G. https://orcid.org/0000-0002-9589-585X
Koide, Shohei https://orcid.org/0000-0001-5473-4358
Liu, Weifeng
Toenjes, Sean T.
Jardine, Paul Da Silva
Chopra, Rajesh
Rader, Christoph https://orcid.org/0000-0001-9955-3454
Stopfer, Lauren E. https://orcid.org/0000-0001-6984-3004
- License Information
-
More Information
Article History
Received: 21 March 2025
Accepted: 30 October 2025
First Online: 17 December 2025
Competing interests
: L.M., S.A.M., S.A.R.-A., A.P., D.N.M., M.S., S.S., T.A., B.V., W.L., S.T.T., P.D.S.J., R.C., C.R., and L.E.S. are or were previously employees of Aethon Therapeutics and hold equity. BGN and SK hold equity in Aethon Therapeutics. BGN’s spouse holds equity in Revolution Medicines and owned equity in Mirati Therapeutics and Amgen during the course of this work. The remaining authors declare no competing interests.
